JP2013509392A5 - - Google Patents

Download PDF

Info

Publication number
JP2013509392A5
JP2013509392A5 JP2012535977A JP2012535977A JP2013509392A5 JP 2013509392 A5 JP2013509392 A5 JP 2013509392A5 JP 2012535977 A JP2012535977 A JP 2012535977A JP 2012535977 A JP2012535977 A JP 2012535977A JP 2013509392 A5 JP2013509392 A5 JP 2013509392A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
hydrogen
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012535977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013509392A (ja
JP5784620B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/054749 external-priority patent/WO2011051858A1/en
Publication of JP2013509392A publication Critical patent/JP2013509392A/ja
Publication of JP2013509392A5 publication Critical patent/JP2013509392A5/ja
Application granted granted Critical
Publication of JP5784620B2 publication Critical patent/JP5784620B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012535977A 2009-10-28 2010-10-20 カゼインキナーゼ阻害剤としてのイミダゾール誘導体 Active JP5784620B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25550609P 2009-10-28 2009-10-28
US61/255,506 2009-10-28
PCT/IB2010/054749 WO2011051858A1 (en) 2009-10-28 2010-10-20 Imidazole derivatives as casein kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2013509392A JP2013509392A (ja) 2013-03-14
JP2013509392A5 true JP2013509392A5 (enExample) 2013-11-28
JP5784620B2 JP5784620B2 (ja) 2015-09-24

Family

ID=43301770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535977A Active JP5784620B2 (ja) 2009-10-28 2010-10-20 カゼインキナーゼ阻害剤としてのイミダゾール誘導体

Country Status (22)

Country Link
US (1) US8518944B2 (enExample)
EP (1) EP2493876B1 (enExample)
JP (1) JP5784620B2 (enExample)
KR (1) KR101421852B1 (enExample)
CN (1) CN102686580B (enExample)
AR (1) AR078797A1 (enExample)
AU (1) AU2010311035B2 (enExample)
CA (1) CA2777632C (enExample)
DK (1) DK2493876T3 (enExample)
ES (1) ES2460065T3 (enExample)
HR (1) HRP20140252T1 (enExample)
IL (1) IL219190A0 (enExample)
IN (1) IN2012DN03182A (enExample)
MX (1) MX2012004997A (enExample)
PL (1) PL2493876T3 (enExample)
PT (1) PT2493876E (enExample)
RS (1) RS53246B (enExample)
SI (1) SI2493876T1 (enExample)
TW (1) TW201125864A (enExample)
UY (1) UY32977A (enExample)
WO (1) WO2011051858A1 (enExample)
ZA (1) ZA201202776B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509919A (ja) 2006-11-15 2010-04-02 マサチューセッツ・アイ・アンド・イア・インファーマリー 内耳細胞の生成
SI2654750T1 (sl) * 2010-12-20 2017-04-26 Pfizer Inc. Nove kondenzirane piridinske spojine kot inhibitorji kazein-kinaz
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
JP6267231B2 (ja) 2012-12-21 2018-01-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カゼインキナーゼ1δ/ε阻害剤としての新規な置換イミダゾール
WO2014192868A1 (ja) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 環状アミノメチルピリミジン誘導体
WO2015119579A1 (en) 2014-02-07 2015-08-13 Agency For Science, Technology And Research 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
US10722513B2 (en) 2015-03-23 2020-07-28 The University Of Melbourne Treatment of respiratory diseases
US11185536B2 (en) * 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
AU2017212655B2 (en) 2016-01-29 2024-01-18 Decibel Therapeutics, Inc. Expansion and differentiation of inner ear supporting cells and methods of use thereof
WO2018201192A1 (en) * 2017-05-03 2018-11-08 The University Of Melbourne Compounds for the treatment of respiratory diseases
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
CN113301900B (zh) * 2018-09-09 2024-11-29 夸纳特制药股份公司 酪蛋白激酶1抑制剂在治疗血管疾病中的应用
AU2019374731B2 (en) * 2018-11-07 2025-08-21 Tianli Biotech Pty Ltd Compounds and compositions for the treatment of respiratory diseases
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
WO2021190616A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Methods for inhibiting casein kinases
EP4126878A4 (en) * 2020-03-27 2024-07-10 Gritscience Biopharmaceuticals Co., Ltd. COMPOUNDS AS CASEIN KINASE INHIBITORS
AR122711A1 (es) * 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012154A1 (en) * 1990-12-31 1992-07-23 Fujisawa Pharmaceutical Co., Ltd. Imidazotriazine derivatives
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
JP2000507558A (ja) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Cns損傷についての新規な治療
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
EP1404864A4 (en) * 2001-06-18 2008-05-28 Univ Rockefeller REGULATION OF NEURONAL FUNCTION OVER SIGNAL PATHS OF THE METABOTROPIC GLUTAMATE RECEPTOR
JP4691506B2 (ja) * 2003-12-11 2011-06-01 アベンティス・ファーマスーティカルズ・インコーポレイテツド カゼインキナーゼIεの阻害剤としての置換1H−ピロロ[3,2−b,3,2−c,及び2,3−c]ピリジン−2−カルボキシアミド及び関連類似物
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
ES2334927T3 (es) * 2004-08-19 2010-03-17 Aventis Pharmaceuticals Inc. Derivados de 3-ariltioindol-2-carboxamida y sus analogos como imhibidores de caseina quinasa i.
ATE517874T1 (de) * 2005-10-21 2011-08-15 Exelixis Inc Pyrimidinone als modulatoren von caseinkinase ii (ck2)
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
SI2654750T1 (sl) 2010-12-20 2017-04-26 Pfizer Inc. Nove kondenzirane piridinske spojine kot inhibitorji kazein-kinaz

Similar Documents

Publication Publication Date Title
JP2013509392A5 (enExample)
RU2353616C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JP2017502940A5 (enExample)
JP2018524390A5 (enExample)
WO2009082268A3 (ru) ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
JP2016540742A5 (enExample)
CA2450922A1 (en) Piperidines for use as orexin receptor antagonists
AR066043A1 (es) Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1)
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
JP2015143283A5 (enExample)
JP2012511588A5 (enExample)
JP2014511892A5 (enExample)
MX2015017343A (es) Derivados de pirrolopiridina o pirazolopiridina.
JP2016503797A5 (enExample)
JP2013533253A5 (enExample)
EA201391341A1 (ru) Производные гетероциклических аминов
RU2014152790A (ru) Пирролопиразоновые ингибиторы танкиразы
JP2012097115A5 (enExample)
JP2020527175A5 (enExample)
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
RU2007106180A (ru) Производные индола, индазола или индолина
JP2008513485A5 (enExample)
AR072809A1 (es) Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende
JP2006523698A5 (enExample)